Analyst Update: Concordia International Corp, salesforce.com, inc., and Select Comfort Corp.

Analysts revised their ratings and price targets on Concordia International Corp (CXRX), salesforce.com, inc. (CRM), and Select Comfort Corp. (SCSS)

by Alex Eppstein

Published on Aug 15, 2016 at 2:18 PM

Analysts are weighing in on drugmaker Concordia International Corp (NASDAQ:CXRX), cloud concern salesforce.com, inc. (NYSE:CRM), and Sleep Number parent Select Comfort Corp. (NASDAQ:SCSS). Here's a quick roundup of today's brokerage notes on CXRX, CRM, and SCSS.

  • CXRX has dropped 4.2% at $9.70, and earlier touched a two-year low of $9.08, after getting hit with a raft of negative analyst attention. Specifically, CIBC cut its rating to "sector underperformer" from "sector performer," and slashed its price target to $7.80 from $27.50. TD Securities, Goldman Sachs, and Canaccord Genuity likewise lowered their target prices on Concordia International Corp., which was demolished after earnings on Friday. These technical struggles are music to the ears of option bears. During the last two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have bought to open 3.98 puts for every call. In separate news, CXRX just announced a cross-currency swap to "further align its British pound-sterling earnings and strong free cash flow with its debt obligations."
  • CRM is down 2.9% at $79.29, following a report that OTR Global lowered its opinion to "mixed" from "positive." Separately, the company said it has delayed its second-quarter earnings report by two days, to the evening of Wednesday, Aug. 31. Technically, since hitting a record high above $84 in late May, salesforce.com, inc. shares have been consolidating around $80. While today's drop is steep, it appears the stock has found a foothold atop its 100-day moving average. Meanwhile, negative attention has been exceedingly rare among analysts, today's activity excepted. In fact, 26 brokerage firms rate CRM a "strong buy," compared to three "holds" and not a single "sell."
  • While the two aforementioned stocks are breaking down, SCSS earlier broke out to an annual high of $28.34. At last check, the shares were still 9.4% higher at $28.18, buoyed by an upgrade to "overweight" from "neutral" at Piper Jaffray. "As SCSS moves past its transformation/investment years, capital spending and acquisitions are expected to decline," said the brokerage firm in a note. In addition, Piper Jaffray lifted its price target on Select Comfort Corp. by $8 to $31. A capitulation among short sellers could lead the shares to even higher highs, as well. Currently, one-tenth of SCSS' float is dedicated to short interest, and it would take over a week for these bears to cover their positions, based on the stock's average trading volume.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.